Newer targeted therapies are being linked with medication-related osteonecrosis of the jaw, which underscores the need to stay abreast of its risk factors and etiologies.
After reading this course, the participant should be able to:
- Describe risk factors for medication-related osteonecrosis of the jaw (MRONJ), including gender prevalence and anatomical sites most commonly affected.
- Explain diagnostic considerations and staging for MRONJ lesions.
- Discuss screening, prevention and management of MRONJ in patients undergoing targeted cancer therapies.
This course was issued in February 2021 and expires February 2024. The authors have no commercial conflicts of interest to disclose. This 2 credit hour self-study activity is electronically mediated.